Psychotic Disorder Clinical Trial
— TESOROOfficial title:
Treating Early Stages Of seveRe Mental disOrders With an Intervention Targeting Cognitive Reserve
NCT number | NCT05288049 |
Other study ID # | HCLinic |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2021 |
Est. completion date | January 2023 |
This study proposes continuity in the implementation of a psychological approach program to enhance cognitive reserve (CR) in children, adolescent and young adults, off-springs of patients with schizophrenia or bipolar disorder (Off-SZBP), and first affective and non-affective episodes with three main objectives: to characterize the cognitive reserve in the early stages of the disease, to validate the adaptation of the intervention to first affective and non-affective disorders to assess the effectiveness of the intervention in a longer term.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | January 2023 |
Est. primary completion date | January 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. - Inclusion criteria for the Off-SZBP will be: Subjects between 12 and 25 years with a parent (mother or father) diagnosed with bipolar disorder or schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria. 2. - Inclusion criteria for patients with a first affective (mania or depression with or without psychotic symptoms and hypomania) or non-affective episode (first psychotic episode) will be: 1. Patients between 12 and 45 years with a first affective or non-affective episode within the last 5 years. 2. Diagnosis of bipolar disorder, schizophrenia, schizoaffective disorders and other psychoses according to DSM-5 criteria based on a semi-structured clinical interview. 3. Patients in full or partial clinical remission at the moment of assessment, defined as scores = 10 in Young Mania Rating Scale (YMRS) (Young, 1978) and = 14 scores in the Hamilton Depression Rating Scale (Hamilton, 1960). 4. Scores lower or equal to 3 during the previous two months in symptoms P1 (delusions), G9 (unusual thought content), P3 (hallucinations), P2 (conceptual disorganization), G5 (mannerisms and posturing), N1 (blunted affect), N4 (social withdrawal) and N6 (spontaneity and flow of conversation) on the scale for positive and negative schizophrenia syndrome (PANSS). 3. - Inclusion criteria for Community Control:s (CC) Children, adolescents and young adults between 12 and 45 years old without history of psychotic disorder or bipolar disorder in first degree relatives. - Exclusion criteria, common to all participants, will be: 1. Estimated Intelligence quotient < 70. 2. Any medical condition that could affect neuropsychological performance (such as neurological diseases) or history of head trauma with loss of consciousness. 3. To have participated in any structured psychosocial intervention within the past 6 months. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clinic | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Hospital Clinic of Barcelona |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | cognitive reserve | the enhancing of cognitive reserve by means of the Cognitive Reserve Assessment Scale (CRASH scale). The CRASh scale is an interviewer-administered instrument which consists of 23 items to assess three domains related with the cognitive reserve: education, occupation and leisure and intellectual activities. This last domain will have evaluated taking into account the different life stages (childhood/adolescence, adulthood and current situation). The scale provides a total score and different scores for each specific domain. The maximum total score is 60 points. Each domain scores is calculated by adding all items of the domain. The higher scores, the higher CR level. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Active, not recruiting |
NCT00627029 -
Evaluation of Programs of Coordinated Care and Disease Management
|
N/A | |
Terminated |
NCT00049738 -
Screening for Childhood-Onset Psychotic Disorders
|
N/A | |
Withdrawn |
NCT01724372 -
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
|
N/A | |
Completed |
NCT00716755 -
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
|
N/A | |
Completed |
NCT00498550 -
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
|
Phase 4 | |
Terminated |
NCT04140773 -
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
|
N/A | |
Completed |
NCT01473550 -
Mental Health Engagement Network (MHEN)
|
N/A | |
Completed |
NCT01207219 -
Yoga and Aerobic Exercise in Psychosis
|
N/A | |
Completed |
NCT00397033 -
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
|
Phase 3 | |
Recruiting |
NCT04945278 -
Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability
|
N/A | |
Completed |
NCT03955250 -
Mobile After-Care Support App: Pilot RCT
|
N/A | |
Completed |
NCT00287352 -
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
|
Phase 1 | |
Completed |
NCT00005658 -
Glycine to Treat Psychotic Disorders in Children
|
Phase 2 | |
Terminated |
NCT00169026 -
Alcoholism and Schizophrenia: Effects of Clozapine
|
Phase 4 | |
Completed |
NCT00001482 -
New Drugs in the Treatment of Mood Disorders
|
Phase 2 | |
Terminated |
NCT03671005 -
Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders
|
N/A | |
Completed |
NCT00156715 -
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
|
Phase 4 | |
Completed |
NCT00095524 -
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
Completed |
NCT03667729 -
The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia
|
N/A |